Prelude Therapeutics Inc (NAS:PRLD)

$ 3.82 0.115 (3.1%) Market Cap: 209.83 Mil Enterprise Value: 18.95 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 38/100

Prelude Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Prelude Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Prelude Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023
Prelude Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Prelude Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023
Prelude Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
Prelude Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Mar 17, 2022
Prelude Therapeutics Inc at Evercore ISI HealthCONx Virtual Conference Transcript
Dec 01, 2021
Prelude Therapeutics Inc at H C Wainwright Precision Oncology Conference (Virtual) Transcript
Oct 20, 2021
Prelude Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Prelude Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021
Prelude Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 12, 2021
Prelude Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 10, 2021

Prelude Therapeutics Inc at Evercore ISI HealthCONx Virtual Conference Transcript

Dec 01, 2021 / 02:15PM GMT

Release Date Price: $13.75 (-3.78%)

Transcript

Josh Schimmer

Evercore Inc. - Analyst

Welcome, everyone. It is Josh Schimmer from the Evercore ISI biotech team. Pleased to introduce Prelude Therapeutics.

Questions & Answers

Josh Schimmer

Evercore Inc. - Analyst

Kris, give us a quick snapshot of Prelude and what you have going on there.

Kris Vaddi

Prelude Therapeutics Incorporated - CEO

Great. Sure, Josh, thanks. Thank you very much for the opportunity to participate in the fireside. Joining with me today is our Chief Scientific Officer, Peggy Scherle; and our Chief Financial Officer, Laurent Chardonnet. So we are excited to participate in this meeting. And for those of you in the audience that are new to Prelude's story, we are a clinical stage precision oncology company with a pipeline of novel compounds targeting validated pathways in cancer, all internally discovered.

We were founded in 2016 with a vision of building a precision oncology company from scratch -- a fully integrated company. And since our inception, we've been focused on

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.